Eilean Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Eilean Therapeutics is a private, preclinical-stage biotech targeting treatment-resistant hematological cancers through a pipeline of novel small molecules. Its strategy centers on developing 'pan-variant' inhibitors that address multiple resistance mutations and escape pathways simultaneously, aiming to create more durable therapies. The company has a broad early pipeline targeting high-value oncogenic drivers like FLT3/IRAK4, BCL2, and Menin, with its most advanced program, a JAK2 V617F inhibitor, having entered first-in-human studies. Backed by experienced leadership and venture capital investors like OrbiMed, Eilean is positioned to tackle a significant unmet need in oncology.

OncologyHematology

Technology Platform

Focus on designing pan-variant small molecule inhibitors that target multiple resistance mutations and parallel escape pathways simultaneously in hematologic cancers, with an emphasis on wild-type sparing selectivity.

Opportunities

The significant unmet need in treatment-resistant hematologic cancers presents a large and growing market.

Successfully demonstrating that pan-variant inhibition leads to more durable responses could allow Eilean's therapies to become standard of care, capturing value in both later-line and front-line settings.

The broad preclinical pipeline offers multiple shots on goal and potential for out-licensing or partnerships in solid tumors.

Risk Factors

High scientific risk that its novel pan-variant approach may not translate into clinical efficacy or may have unforeseen toxicities.

As a pre-revenue company with an early-stage pipeline, it faces substantial financial risk and will require significant additional capital, leading to potential dilution.

Intense competition in core target areas (FLT3, BCL2, JAK2) from larger, better-funded companies.

Competitive Landscape

Eilean operates in highly competitive spaces. In AML, it faces established FLT3 inhibitors (Astellas' gilteritinib, Daiichi Sankyo's quizartinib) and emerging Menin inhibitors (Kura Oncology, Syndax). In B-cell malignancies, BTK and BCL2 inhibitors are dominated by large pharma. Its differentiation hinges on superior efficacy against resistance mutations, but it must compete against numerous other companies pursuing next-generation inhibitors and novel modalities.

More companies in Oncology (General) →More companies in United States →